Long-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-Positive breast cancer after preoperative systemic therapy: an observational cohort study-Reference-Cited by-同舟云学术

Long-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-Positive breast cancer after preoperative systemic therapy: an observational cohort study

Published:2024-04 Issue: Volume:32 Page:100712
ISSN:2667-193X
Container-title:The Lancet Regional Health - Americas
language:en
Short-container-title:The Lancet Regional Health - Americas

Author:

He Xuexin,Ji Jiali,Qdaisat Aiham,Esteva Francisco J.,Yeung Sai-Ching J.

Funder

National Natural Science Foundation of China

Science and Technology Project of Nantong City

Publisher

Elsevier BV

Reference38 articles.

1. Long-term quality of Life in patients with breast cancer after breast conservation vs mastectomy and reconstruction;Hanson;JAMA Surg,2022

2. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment;Rodriguez-Ruiz;Nat Immunol,2020

3. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials;Asselain;Lancet Oncol,2018

4. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: a meta-analysis;Criscitiello;Eur J Cancer,2018

5. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Which real indications remain for mastectomy?;The Lancet Regional Health - Americas;2024-05